"Progestins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.
| Descriptor ID |
D011372
|
| MeSH Number(s) |
D27.505.696.399.472.858
|
| Concept/Terms |
Progestins- Progestins
- Progestagens
- Progestational Hormones
- Progestogens
- Gestagen
- Progestational Compounds
- Progestagenic Agents
- Gestagenic Agents
- Progestin
- Gestagens
- Progestational Agents
Progestin Effect- Progestin Effect
- Effect, Progestin
- Progestogen Effect
- Effect, Progestogen
- Gestagenic Effects
- Effects, Gestagenic
- Gestagen Effect
- Effect, Gestagen
- Gestagen Effects
- Effects, Gestagen
- Gestagenic Effect
- Effect, Gestagenic
- Progestin Effects
- Effects, Progestin
- Progestogen Effects
- Effects, Progestogen
|
Below are MeSH descriptors whose meaning is more general than "Progestins".
Below are MeSH descriptors whose meaning is more specific than "Progestins".
This graph shows the total number of publications written about "Progestins" by people in this website by year, and whether "Progestins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Progestins" by people in Profiles.
-
Progesterone Treatment Does Not Decrease Serum Levels of Biomarkers of Glial and Neuronal Cell Injury in Moderate and Severe Traumatic Brain Injury Subjects: A Secondary Analysis of the Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment (ProTECT) III Trial. J Neurotrauma. 2021 07 15; 38(14):1953-1960.
-
CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. Br J Cancer. 2016 Jan 19; 114(2):221-9.
-
Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat. 2016 Jan; 155(1):3-12.
-
17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol. 2012 Nov; 207(5):390.e1-8.
-
Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance. J Reprod Med. 2009 Feb; 54(2):47-52.
-
Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance. Am J Obstet Gynecol. 2008 Oct; 199(4):389.e1-4.
-
Breast cancer: the role of hormone therapy. Semin Reprod Med. 2005 May; 23(2):167-71.
-
Postmenopausal hormone replacement therapy: does the progestin make a difference? J S C Med Assoc. 2002 Feb; 98(1):12-9.
-
Recommendations regarding estrogen replacement therapy after treatment of endometrial cancer. Oncology (Williston Park). 1992 Jul; 6(7):23-6; discussion 26, 28.
-
Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol. 1979 Mar 01; 133(5):537-47.